Linvoseltamab (Lynozyfic, Regeneron) is a BCMA-targeting bispecific antibody that was FDA-approved on July 2, 2025, for people with relapsed or refractory myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. 

How often is linvoseltamab given?

Linvoseltamab is given as an intravenous (IV) infusion. The initial treatment involves a specific dosing schedule with "step-up" priming doses, followed by weekly infusions. At week 14, infusions are given every other week. If you experience and maintain a very good partial response (VGPR) or better at or after week 24 and have received at least 17 doses of 200 mg, you may move to 1 infusion every 4 weeks. 

How effective is linvoseltamab for relapsed/refractory myeloma?

In the LINKER-MM1 study, 45% of patients experienced a complete response or better, and 6% a partial response. At a median follow-up of 11.3 months, 89% of patients remained in remission (duration of response). 

Side effects 

In the LINKER-MM1 study, 46% of patients experienced some grade of CRS and 54% some grade of neurologic toxicities, including ICANS. Additionally, 62% of patients receiving teclistamab experienced low numbers of a specific type of white blood cell (called a neutrophil), a condition known as neutropenia, which raises the risk for serious infections. To learn more about these effects, see: Linvoseltamab Safety Profile.  

Understanding these risks may help guide conversations with your doctor on how to best prepare for treatment. If you have questions about how side effects are managed with supportive care, please ask your myeloma specialist. Additionally, you can access the guide section: Side Effect Management and Support.

For more information on linvoseltamab, visit lynozyfic.com